Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
| ▸ | PDE4A | P27815 | 1/20 | 0.38 |
| ▸ | SLC6A6 | P31641 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | APP | P05067 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 4/20 | 0.33 |
| ▸ | CA2 | P00918 | 4/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MMP9 | P14780 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28180126 | 0.85 | CA1 (0.36) | LMNAPTGS1PDE4ASLC6A6CYP2C19 | |
| SCHEMBL27886057 | 0.81 | CA1 (0.35) | LMNACA1CA2KDM4EUSP2 | |
| SCHEMBL17239111 | 0.81 | PTGS1 (0.39) | LMNAPTGS1PDE4ASLC6A6CYP2C19 | |
| SCHEMBL9543126 | 0.80 | CA1 (0.41) | LMNABLMCA1CA2KDM4E | |
| SCHEMBL4572909 | 0.79 | CA1 (0.36) | LMNACA1CA2KDM4EUSP2 | |
| SCHEMBL27910832 | 0.78 | CA1 (0.44) | LMNAPTGS1PDE4ASLC6A6CYP2C19 | |
| SCHEMBL30164353 | 0.77 | CA1 (0.39) | LMNABLMCA1CA2KDM4E | |
| SCHEMBL25630346 | 0.77 | CA1 (0.40) | CA1CA2 | |
| SCHEMBL524165 | 0.77 | LMNA (0.36) | LMNAPTGS1PDE4ASLC6A6CYP2C19 | |
| SCHEMBL565251 | 0.76 | USP2 (0.57) | LMNAPTGS1PDE4ASLC6A6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2245029-B1 | HETEROCYCLIC INHIBITORS OF STEAROYL-COA DESATURASE | NOVARTIS AG (CH) | 2015-04-15 | — | — | EP | disclosed |
| EP-2380889-B1 | Thiazolyl MGLUR5 antagonists and methods for their use | MERCK SHARP & DOHME (US) | 2013-06-26 | — | — | EP | disclosed |
| EP-2380889-A2 | Thiazolyl MGLUR5 antagonists and methods for their use | Merck Sharp & Dohme Corp. (US) | 2011-10-26 | — | — | EP | disclosed |
| EP-1893608-B1 | THIAZOLYL MGLUR5 ANTAGONISTS AND METHODS FOR THEIR USE | MERCK SHARP & DOHME (US) | 2011-08-17 | — | — | EP | disclosed |
| EP-1893608-A4 | THIAZOLYL MGLUR5 ANTAGONISTS AND METHODS FOR THEIR USE | MERCK & CO INC (US) | 2009-04-22 | — | — | EP | disclosed |
| EP-1893608-A2 | THIAZOLYL MGLUR5 ANTAGONISTS AND METHODS FOR THEIR USE | Merck and Co., Inc. (US) | 2008-03-05 | — | — | EP | disclosed |
| EP-1874724-A2 | PHENYL ETHYNE COMPOUNDS | Merck & Co., Inc. (US) | 2008-01-09 | — | — | EP | disclosed |
| WO-2007050050-A2 | THIAZOLYL MGLUR5 ANTAGONISTS AND METHODS FOR THEIR USE | MERCK & CO., INC. (US) | 2007-05-03 | — | — | WO | disclosed |
| WO-2006115895-A2 | PHENYL ETHYNE COMPOUNDS | MERCK & CO., INC. (US) | 2006-11-02 | — | — | WO | disclosed |
| US-20030055247-A1 | Thiazolyl(pyridyl)ethyne compounds | MERCK SHARP & DOHME CORP. | 2003-03-20 | — | — | US | disclosed |
| EP-1214303-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | Merck & Co., Inc. (US) | 2002-06-19 | — | — | EP | disclosed |
| WO-2001016121-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | MERCK & CO., INC. (US) | 2001-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030055247-A1 | Thiazolyl(pyridyl)ethyne compounds | CBR3, CBR1, CHRM3 | LMNA 4565/4885PTGS1 1564/4885PDE4A 1071/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.